January 25, 2021 – Roche (Basel, Switzerland) announced that, on December 14, 2020, it signed a Global Business Partnership Agreement (GBPA) with Sysmex.
Sysmex and Roche initially signed a GBPA on December 14, 2020 to form a framework for their alliance and commenced activities accordingly on January 1, 2021. The GBPA includes the DSSA and the TLSA, as well as an IT Solutions Collaboration Agreement, and the two companies have agreed to develop a next-generation global alliance.
Roche will continue to distribute and support Sysmex hematology products in selected countries in Central and South America, Europe, southern Africa, and Oceania. Sysmex plans to boost direct sales and support structures in Spain and India, both of which were added
to their list of territories pursuant to the TLSA, in a bid to increase the resilience of the two companies’ global sales and service network.
This GBPA also introduced an IT Solutions Collaboration Agreement. In the newly defined collaboration, the two companies have agreed to utilize their respective IT platforms to improve customer experience in the short to mid-term, with a longer term ambition to use the IT systems to lead to improved clinical decision making.
The GBP agreement will run until the end of 2030.